Jesse Solomon

Davis Polk is advising Clarivate Analytics plc in connection with its $950 million acquisition of Decision Resources Group from Piramal Enterprises Limited. The $950 million purchase price…

Davis Polk advised Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc., including coordinating all international regulatory filings.  The acquisition was…

Davis Polk is advising Attunity Ltd. on its approximately $560 million acquisition by Qlik Technologies Inc. The transaction, which is expected to close in the second quarter of 2019, is…

Davis Polk is advising Millicom International Cellular S.A. on its $1.65 billion acquisition of the entire share capital of Telefónica Móviles Panamá, S.A., Telefónica de Costa Rica TC, S.A…

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…

Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…

Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…

Davis Polk, together with Slaughter and May, is advising Shire plc in connection with a recommended cash and stock offer for Shire’s entire share capital by Takeda Pharmaceutical Company…

Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…